Hepion Pharmaceuticals Inc. [NASDAQ: HEPA] loss -0.60% on the last trading session, reaching $1.65 price per share at the time. The company report on March 23, 2021 that DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431.
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”) – driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, announced positive results from an in vivo study of CRV431 in a Diet-Induced Animal Model Of Non-alcoholic fatty liver Disease (“DIAMOND”).1.
It is estimated by the National Institutes of Health, that between 3% – 12% of the U.S. adult population has NASH.2 There are currently at least 90 drug candidates targeting NASH in various stages of development.3 The majority of these drug candidates are designed to target metabolic perturbations leading to the pathogenesis of NASH and thereby seek to normalize glycemic control, lipid metabolism, and insulin resistance, to name a few. Few drug candidates directly target fibrosis, either through fibrogenesis and/or fibrolysis, despite fibrosis being a major prognostic indicator of liver-related and overall mortality.4 Hepion’s clinical drug candidate, CRV431 administered once daily orally, seeks to target fibrosis, and the company’s latest in vivo animal study further lends validity to this mechanism.
Hepion Pharmaceuticals Inc. represents 76.23 million in outstanding shares, while the company has a total market value of $126.51 million with the latest information. HEPA stock price has been found in the range of $1.58 to $1.67.
If compared to the average trading volume of 6.44M shares, HEPA reached a trading volume of 3149396 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Hepion Pharmaceuticals Inc. [HEPA]:
ROTH Capital have made an estimate for Hepion Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 20, 2020.
The Average True Range (ATR) for Hepion Pharmaceuticals Inc. is set at 0.14 The Price to Book ratio for the last quarter was 0.71, with the Price to Cash per share for the same quarter was set at 0.53.
Trading performance analysis for HEPA stock
Hepion Pharmaceuticals Inc. [HEPA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.81. With this latest performance, HEPA shares dropped by -25.00% in over the last four-week period, additionally sinking by -52.45% over the last 6 months – not to mention a rise of 9.27% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HEPA stock in for the last two-week period is set at 36.41, with the RSI for the last a single of trading hit 31.89, and the three-weeks RSI is set at 39.42 for Hepion Pharmaceuticals Inc. [HEPA]. The present Moving Average for the last 50 days of trading for this stock 2.1026, while it was recorded at 1.7040 for the last single week of trading, and 2.7454 for the last 200 days.
Hepion Pharmaceuticals Inc. [HEPA]: A deeper dive into fundamental analysis
Return on Total Capital for HEPA is now -69.15, given the latest momentum, and Return on Invested Capital for the company is -70.53. Return on Equity for this stock declined to -71.79, with Return on Assets sitting at -58.31. When it comes to the capital structure of this company, Hepion Pharmaceuticals Inc. [HEPA] has a Total Debt to Total Equity ratio set at 1.86. Additionally, HEPA Total Debt to Total Capital is recorded at 1.82, with Total Debt to Total Assets ending up at 1.52. Long-Term Debt to Equity for the company is recorded at 1.22, with the Long-Term Debt to Total Capital now at 1.14.
Reflecting on the efficiency of the workforce at the company, Hepion Pharmaceuticals Inc. [HEPA] managed to generate an average of -$1,565,688 per employee.Hepion Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.10 and a Current Ratio set at 9.10.
Hepion Pharmaceuticals Inc. [HEPA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Hepion Pharmaceuticals Inc. posted -0.53/share EPS, while the average EPS was predicted by analysts to be reported at -0.96/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 44.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HEPA.
An analysis of insider ownership at Hepion Pharmaceuticals Inc. [HEPA]
There are presently around $9 million, or 12.60% of HEPA stock, in the hands of institutional investors. The top three institutional holders of HEPA stocks are: VANGUARD GROUP INC with ownership of 1,728,604, which is approximately New of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 1,194,434 shares of the stock with an approximate value of $1.97 million in HEPA stocks shares; and AIGH CAPITAL MANAGEMENT LLC, currently with $1.52 million in HEPA stock with ownership of nearly New of the company’s market capitalization.
Positions in Hepion Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 27 institutional holders increased their position in Hepion Pharmaceuticals Inc. [NASDAQ:HEPA] by around 5,356,622 shares. Additionally, 10 investors decreased positions by around 162,353 shares, while 5 investors held positions by with 55,992 shares. The mentioned changes placed institutional holdings at 5,462,983 shares, according to the latest SEC report filing. HEPA stock had 20 new institutional investments in for a total of 3,924,814 shares, while 7 institutional investors sold positions of 118,945 shares during the same period.